APA

van Vollenhoven R. F., Ernestam S., Geborek P., Petersson I. F., Cöster L., Waltbrand E., Zickert A., Theander J., Thörner A., Hellström H., Teleman A., Dackhammar C., Akre F., Forslind K., Ljung L., Oding R., Chatzidionysiou A., Wörnert M. & Bratt J. (20090908). Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. : Lancet (London, England).

Chicago

van Vollenhoven R F, Ernestam S, Geborek P, Petersson I F, Cöster L, Waltbrand E, Zickert A, Theander J, Thörner A, Hellström H, Teleman A, Dackhammar C, Akre F, Forslind K, Ljung L, Oding R, Chatzidionysiou A, Wörnert M and Bratt J. 20090908. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. : Lancet (London, England).

Harvard

van Vollenhoven R. F., Ernestam S., Geborek P., Petersson I. F., Cöster L., Waltbrand E., Zickert A., Theander J., Thörner A., Hellström H., Teleman A., Dackhammar C., Akre F., Forslind K., Ljung L., Oding R., Chatzidionysiou A., Wörnert M. and Bratt J. (20090908). Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. : Lancet (London, England).

MLA

van Vollenhoven R F, Ernestam S, Geborek P, Petersson I F, Cöster L, Waltbrand E, Zickert A, Theander J, Thörner A, Hellström H, Teleman A, Dackhammar C, Akre F, Forslind K, Ljung L, Oding R, Chatzidionysiou A, Wörnert M and Bratt J. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. : Lancet (London, England). 20090908.